De novo resistance to TAS-117 can be overcome by administering a combination treatment comprising chemotherapy, targeted therapy, and immunotherapy and including TAS-117 in earlier treatment lines in patients with breast and ovarian cancers to target PIK3CA E545K, H1047R, and Akt1E17K mutations. Here, PIK3CA is linked to ovarian carcinoma.